XERIS BIOPHARMA HOLDINGS, INC. (XERS) EBITDA
- 2026-06-30: Basis Reported; EBITDA $5.50M*; Operating income $5.17M; Depreciation and amortization $323.00K*.
- 2026-03-31: Basis Reported; EBITDA $8.25M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $17.11M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA $7.07M*; Operating income $6.73M; Depreciation and amortization $338.00K*.
Complete source-backed ebitda history.
- Available history
- 2020-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | $5.50M* | $5.17M | $323.00K* | $92.10M | 5.97%* | (m) | $8.26M* | (m) | $10.67M | $61.03M | $0.00 |
|---|
| 2026-03-31 | Reported | $8.25M | (m) | (m) | (m) | 9.93% | (m) | $9.87M | (m) | $8.78M | $53.14M | $0.00 |
|---|
| 2025-12-31 | Reported | $17.11M | (m) | (m) | (m) | 19.94% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | $7.07M* | $6.73M | $338.00K* | $74.38M | 9.50%* | (m) | $18.43M* | (m) | $7.48M | $46.46M | $0.00 |
|---|
| 2025-06-30 | Reported | $4.81M* | $4.48M | $325.00K* | $71.54M | 6.72%* | (m) | $182.00K* | (m) | $8.05M | $44.39M | $0.00 |
|---|
| 2025-03-31 | Reported | -$2.78M | (m) | (m) | (m) | -4.62% | (m) | -$10.03M | (m) | $7.75M | $44.02M | $0.00 |
|---|
| 2024-12-31 | Reported | $1.99M | (m) | (m) | (m) | 3.31% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$12.59M* | -$12.89M | $307.00K* | $54.27M | -23.19%* | (m) | -$8.30M* | (m) | $5.89M | $44.97M | -$3.32M |
|---|
| 2024-06-30 | Reported | -$7.91M* | -$8.19M | $281.00K* | $48.06M | -16.45%* | (m) | -$10.35M* | (m) | $5.76M | $39.99M | $749.00K |
|---|
| 2024-03-31 | Reported | -$13.92M | (m) | (m) | (m) | -34.25% | (m) | -$20.30M | (m) | $7.82M | $38.38M | $307.00K |
|---|
| 2023-12-31 | Reported | -$9.5M | (m) | (m) | (m) | -21.39% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$4.52M* | -$4.91M | $391.00K* | $48.32M | -9.36%* | (m) | -$14.61M* | (m) | $5.03M | $37.29M | -$338.00K |
|---|
| 2023-06-30 | Reported | -$15.59M* | -$15.98M | $386.00K* | $38.01M | -41.03%* | (m) | -$13.74M* | (m) | $6.09M | $37.63M | -$675.00K |
|---|
| 2023-03-31 | Reported | -$12.91M | (m) | (m) | (m) | -38.90% | (m) | -$26.14M | (m) | $4.84M | $33.60M | $0.00 |
|---|
| 2022-12-31 | Reported | -$14.8M | (m) | (m) | (m) | -44.67% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$18.42M* | -$18.78M | $360.00K* | $29.73M | -61.97%* | (m) | -$17.75M* | (m) | $6.04M | $34.49M | -$339.00K |
|---|
| 2022-06-30 | Reported | -$18.56M* | -$18.92M | $352.00K* | $25.31M | -73.36%* | (m) | -$20.61M* | (m) | $3.72M | $32.98M | -$339.00K |
|---|
| 2022-03-31 | Reported | -$28.75M | (m) | (m) | (m) | -130.26% | (m) | -$48.41M | (m) | $6.25M | $35.91M | -$408.00K |
|---|
| 2021-12-31 | Reported | -$47.92M | (m) | (m) | (m) | -223.63% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$24.04M* | -$24.36M | $323.00K* | $11.06M | -217.31%* | (m) | -$22.61M* | $3.22M | $5.66M | $26.54M | $0.00 |
|---|
| 2021-06-30 | Reported | -$25.47M* | -$25.79M | $320.00K* | $8.91M | -285.95%* | (m) | -$20.02M* | (m) | $5.38M | $25.93M | $0.00 |
|---|
| 2021-03-31 | Reported | -$16.4M | (m) | (m) | (m) | -203.74% | (m) | -$23.96M | (m) | $4.03M | $19.08M | $0.00 |
|---|
| 2020-12-31 | Reported | -$18.9M | (m) | (m) | (m) | -266.57% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | (m) | -$13.74M | (m) | $9.40M | (m) | (m) | (m) | $2.83M | $3.88M | $16.48M | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | $26.21M | (m) | (m) | (m) | 8.98% | (m) | $28.63M | (m) | $31.16M | $182.37M | $0.00 |
|---|
| 2024-12-31 | Reported | -$32.42M | (m) | (m) | (m) | -15.96% | (m) | -$36.98M | (m) | $25.56M | $163.48M | -$2.27M |
|---|
| 2023-12-31 | Reported | -$42.52M | (m) | (m) | (m) | -25.94% | (m) | -$47.02M | (m) | $22.34M | $146.09M | -$1.25M |
|---|
| 2022-12-31 | Reported | -$80.54M | (m) | (m) | (m) | -73.05% | (m) | -$102.89M | (m) | $20.97M | $137.75M | -$1.42M |
|---|
| 2021-12-31 | Reported | -$113.83M | (m) | (m) | (m) | -229.54% | $1.08M | -$95.53M | (m) | $25.16M | $125.72M | $0.00 |
|---|
| 2020-12-31 | Reported | -$82.08M | (m) | (m) | (m) | -407.24% | $377.00K | -$80.56M | (m) | $20.92M | $73.73M | -$110.00K |
|---|